Developer docs
API playgroundTry for free, no card

Search company profiles

Wickenstones

Full company profile

uuid000b4oq

Namestring
Wickenstones
Legal namestring
Wickenstones Limited
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Wickenstones is a privately held B2B consultancy founded in 2013 that delivers integrated evidence, access, commercial, and medical consultancy services to pharmaceutical and biotechnology clients. The firm operates from four offices—Oxford (UK headquarters), London (UK), Carlow (Republic of Ireland), and New York (USA)—with separate registered entities in England and Wales (No. 8576674), the Republic of Ireland (No. 651480), and the United States (No. 7411481). It serves clients across Europe and North America using a horizontal segmentation approach that spans multiple therapeutic areas, including oncology, cardio-renal, pulmonology, vaccines, gastrointestinal, immunology, neuro & CNS, neuromuscular, metabolic conditions, cell & gene therapy, medical devices & diagnostics, and radiology.

The company organises its offering around ten integrated capability areas: Health Technology Assessment, Global Pricing, Evidence Review, Evidence Generation (including real-world evidence), Economic Modelling, Market Research, Value Communications, Route to Market Planning, Stakeholder Engagement, and Organisational Strategy and Design. Services are delivered through dedicated, multidisciplinary teams wrapped around each client, with explicit commitments to bespoke solutions, proactive partnership, and consistent team continuity from pitch through delivery. The underlying "technology" is human expertise—primarily PhD- and MSc-level health economics, market access, and evidence generation professionals—rather than proprietary software platforms; no AI/ML capabilities, APIs, or productised tools are disclosed.

Wickenstones operates a professional services revenue model, generating revenue through project-based consulting engagements priced on a bespoke, quote-based structure tailored to each client's scope. Go-to-market is sales-led and direct enterprise engagement, with the firm relying on LinkedIn thought leadership, website case studies and publications, professional conferences such as ISPOR, and referrals for business development rather than digital storefronts or marketplaces. The firm has 11–50 employees, is founder-led by Eddie Gibson (CEO) with a CXO bench including Alysia Battersby (CTO), James Harris (COO), Dingeman Wolfert (Chief Client Officer), and Aidan Gough (CFO), and has not disclosed any external institutional investors, private equity backing, M&A activity, or public funding rounds.

Short descriptiontext

Wickenstones is a privately held pharma and biotech consultancy delivering integrated evidence, access, commercial, and medical services across ten capability areas—from HTA and pricing to RWE and value communications—for clients in the UK, EU, and US.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAbingdon, United Kingdom
HQ citystring
Abingdon
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
market access consultancy, health economics services, pharmaceutical consulting, HTA submissions, evidence generation
NAICS code2 codes
  • Management Consulting Services54161
  • Management, Scientific, and Technical Consulting Services5416
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Pharmaceutical Market Access and Health Economics Consultancy
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Consulting Services
TypeProfessional Services
Description

Professional consulting services encompassing health technology assessment, global pricing, evidence generation, economic modelling, market research, value communications, route to market planning, stakeholder engagement, and organisational strategy and design. Revenue is generated through project-based consulting engagements with pharmaceutical and life sciences clients.

wickenstones.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Wickenstones is a pharmaceutical and life sciences consultancy providing integrated evidence, access, commercial, and medical advisory services. It delivers ten capability areas — Health Technology Assessment, Global Pricing, Evidence Review, Evidence Generation, Economic Modelling, Market Research, Value Communications, Route to Market Planning, Stakeholder Engagement, and Organisational Strategy and Design — through dedicated, multidisciplinary teams wrapped around each client engagement.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Wickenstones is a consultancy firm providing integrated evidence, access, commercial and medical consultancy services. The company offers ten distinct capability areas that work together as an integrated service offering: Health Technology Assessment, Global Pricing, Evidence Review, Evidence Generation, Economic Modelling, Market Research, Value Communications, Route to Market Planning, Stakeholder Engagement, and Organisational Strategy and Design. These services are delivered through dedicated multidisciplinary teams wrapped around each client, addressing complex challenges across market access, regulatory, medical, and commercial domains.

Product and service10 records
1Health Technology Assessment
CategoryConsultancy Service
Description

Provides HTA landscape analyses, evidence mapping, global-local HTA strategies, and preparation for HTA interactions and early advice meetings to support payer decision-making across markets for pharmaceutical and biotech clients.

2Global Pricing
CategoryConsultancy Service
Description

Delivers evidence-based pricing solutions including global launch sequencing, early-stage pricing assessment, economically justifiable price modelling, and internal pricing frameworks to achieve market access and commercial success for pharmaceutical products.

3Evidence Review
CategoryConsultancy Service
Description

Conducts systematic literature reviews, systematised literature reviews, rapid reviews, and critical reviews to identify and synthesise evidence supporting regulatory and reimbursement objectives for pharmaceutical and biotech clients.

4Evidence Generation
CategoryConsultancy Service
Description

Plans and executes strategically focused real-world evidence (RWE) generation including cross-sectional studies, prospective studies, and retrospective studies to demonstrate product impact and address value proposition gaps for pharmaceutical clients.

5Economic Modelling
CategoryConsultancy Service
Description

Develops scientifically robust health economic models including cost-effectiveness models, budget impact models, capacity models, and decision analytic modelling to demonstrate product value and align with stakeholder needs.

6Market Research
CategoryConsultancy Service
Description

Delivers objective-driven market research providing deep insights into payer, HTA, HCP, and patient preferences through exploratory primary research, descriptive primary research, and market research review to guide market access strategy.

7Value Communications
CategoryConsultancy Service
Description

Crafts value narratives and develops tailored communication materials including global value dossiers, multi-channel communication materials, and animations aligned with stakeholder information needs.

8Route to Market Planning
CategoryConsultancy Service
Description

Develops commercialisation plans including investor planning, evidence planning, route-to-market planning, launch sequencing, and pre- and post-launch access strategy to maximise revenue through achievement of regulatory and access strategies.

9Stakeholder Engagement
CategoryConsultancy Service
Description

Provides stakeholder engagement strategy and activation planning, decision maker and influencer mapping, engagement tools, and stakeholder collaborations including evidence generation and event organisation.

10Organisational Strategy and Design
CategoryConsultancy Service
Description

Offers organisational design services including global, regional and local team reorganisation, process optimisation, governance and systems assessment, skills and capabilities evaluation, and external benchmarking.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dedicated HEOR, market access, real-world evidence, and HTA consultancy serving pharma and biotech — overlapping capability set across all ten of Wickenstones' service areas.

TypeDirect peer
Description

Pharma market access and pricing consultancy offering global pricing strategy, value communications, and stakeholder engagement — comparable capability footprint to Wickenstones.

TypeDirect peer
Description

Strategy consulting firm focused on pharmaceutical and biotech clients, with deep market access, pricing, and HEOR expertise — directly comparable to Wickenstones' service offering.

TypeDirect peer
Description

Boutique pharma market access and HTA consultancy based in the UK, focused on payer engagement, submissions, and value communication — overlapping service mix with Wickenstones.

TypeBroad incumbent
Description

Large-scale life sciences services and analytics provider with an established consulting and HEOR practice; competes for the same enterprise pharma market access and HTA engagements as Wickenstones but at significantly greater scale.

TypeBroad incumbent
Description

Global consulting firm with a life-sciences practice covering pricing, market access, and commercial strategy — competes for enterprise pharma strategy mandates with Wickenstones but at materially greater scale.

TypeDirect peer
Description

Statistical, HEOR, and real-world evidence consultancy serving pharma and biotech — provides market access, HTA support, and economic modelling services comparable to Wickenstones' capabilities.

TypeDirect peer
Description

UK-based market access, HTA, and HEOR consultancy with similar size and specialisation to Wickenstones, serving pharma clients across the UK and EU.

9BIA (Bundesverband der Arzneimittel-Hersteller)
TypeOthers
Description

German pharma industry association providing policy, market access, and HTA-related advisory support — adjacent to Wickenstones' HTA and stakeholder engagement capabilities in the European market.

TypeBroad incumbent
Description

Global management consultancy with a dedicated pharma practice covering market access, launch strategy, and organisational design — broader portfolio but competes for top-tier strategic pharma mandates.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wickenstones

Pharmaceutical Market Access and Health Economics Consultancywickenstones.com

Wickenstones is a privately held pharma and biotech consultancy delivering integrated evidence, access, commercial, and medical services across ten capability areas—from HTA and pricing to RWE and value communications—for clients in the UK, EU, and US.

What Wickenstones does

Wickenstones is a privately held B2B consultancy founded in 2013 that delivers integrated evidence, access, commercial, and medical consultancy services to pharmaceutical and biotechnology clients. The firm operates from four offices—Oxford (UK headquarters), London (UK), Carlow (Republic of Ireland), and New York (USA)—with separate registered entities in England and Wales (No. 8576674), the Republic of Ireland (No. 651480), and the United States (No. 7411481). It serves clients across Europe and North America using a horizontal segmentation approach that spans multiple therapeutic areas, including oncology, cardio-renal, pulmonology, vaccines, gastrointestinal, immunology, neuro & CNS, neuromuscular, metabolic conditions, cell & gene therapy, medical devices & diagnostics, and radiology.

The company organises its offering around ten integrated capability areas: Health Technology Assessment, Global Pricing, Evidence Review, Evidence Generation (including real-world evidence), Economic Modelling, Market Research, Value Communications, Route to Market Planning, Stakeholder Engagement, and Organisational Strategy and Design. Services are delivered through dedicated, multidisciplinary teams wrapped around each client, with explicit commitments to bespoke solutions, proactive partnership, and consistent team continuity from pitch through delivery. The underlying "technology" is human expertise—primarily PhD- and MSc-level health economics, market access, and evidence generation professionals—rather than proprietary software platforms; no AI/ML capabilities, APIs, or productised tools are disclosed.

Wickenstones operates a professional services revenue model, generating revenue through project-based consulting engagements priced on a bespoke, quote-based structure tailored to each client's scope. Go-to-market is sales-led and direct enterprise engagement, with the firm relying on LinkedIn thought leadership, website case studies and publications, professional conferences such as ISPOR, and referrals for business development rather than digital storefronts or marketplaces. The firm has 11–50 employees, is founder-led by Eddie Gibson (CEO) with a CXO bench including Alysia Battersby (CTO), James Harris (COO), Dingeman Wolfert (Chief Client Officer), and Aidan Gough (CFO), and has not disclosed any external institutional investors, private equity backing, M&A activity, or public funding rounds.

Wickenstones firmographics

Firmographics
Name
Wickenstones
Legal name
Wickenstones Limited
Website
https://wickenstones.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Wickenstones is a privately held pharma and biotech consultancy delivering integrated evidence, access, commercial, and medical services across ten capability areas—from HTA and pricing to RWE and value communications—for clients in the UK, EU, and US.
Ownership category
akta.pro rank

Where Wickenstones is headquartered

Location

Headquarters

HQ city
Abingdon
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

Wickenstones business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

  1. Consulting Services: Professional consulting services encompassing health technology assessment, global pricing, evidence generation, economic modelling, market research, value communications, route to market planning, stakeholder engagement, and organisational strategy and design. Revenue is generated through project-based consulting engagements with pharmaceutical and life sciences clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Wickenstones product offering

Product offering

Core offering

Wickenstones is a pharmaceutical and life sciences consultancy providing integrated evidence, access, commercial, and medical advisory services. It delivers ten capability areas — Health Technology Assessment, Global Pricing, Evidence Review, Evidence Generation, Economic Modelling, Market Research, Value Communications, Route to Market Planning, Stakeholder Engagement, and Organisational Strategy and Design — through dedicated, multidisciplinary teams wrapped around each client engagement.

Product overview

Wickenstones is a consultancy firm providing integrated evidence, access, commercial and medical consultancy services. The company offers ten distinct capability areas that work together as an integrated service offering: Health Technology Assessment, Global Pricing, Evidence Review, Evidence Generation, Economic Modelling, Market Research, Value Communications, Route to Market Planning, Stakeholder Engagement, and Organisational Strategy and Design. These services are delivered through dedicated multidisciplinary teams wrapped around each client, addressing complex challenges across market access, regulatory, medical, and commercial domains.

Differentiator

Problem solved

Functional benefit

Products and services

  • Health Technology Assessment Provides HTA landscape analyses, evidence mapping, global-local HTA strategies, and preparation for HTA interactions and early advice meetings to support payer decision-making across markets for pharmaceutical and biotech clients.
  • Global Pricing Delivers evidence-based pricing solutions including global launch sequencing, early-stage pricing assessment, economically justifiable price modelling, and internal pricing frameworks to achieve market access and commercial success for pharmaceutical products.
  • Evidence Review Conducts systematic literature reviews, systematised literature reviews, rapid reviews, and critical reviews to identify and synthesise evidence supporting regulatory and reimbursement objectives for pharmaceutical and biotech clients.
  • Evidence Generation Plans and executes strategically focused real-world evidence (RWE) generation including cross-sectional studies, prospective studies, and retrospective studies to demonstrate product impact and address value proposition gaps for pharmaceutical clients.
  • Economic Modelling Develops scientifically robust health economic models including cost-effectiveness models, budget impact models, capacity models, and decision analytic modelling to demonstrate product value and align with stakeholder needs.
  • Market Research Delivers objective-driven market research providing deep insights into payer, HTA, HCP, and patient preferences through exploratory primary research, descriptive primary research, and market research review to guide market access strategy.
  • Value Communications Crafts value narratives and develops tailored communication materials including global value dossiers, multi-channel communication materials, and animations aligned with stakeholder information needs.
  • Route to Market Planning Develops commercialisation plans including investor planning, evidence planning, route-to-market planning, launch sequencing, and pre- and post-launch access strategy to maximise revenue through achievement of regulatory and access strategies.
  • Stakeholder Engagement Provides stakeholder engagement strategy and activation planning, decision maker and influencer mapping, engagement tools, and stakeholder collaborations including evidence generation and event organisation.
  • Organisational Strategy and Design Offers organisational design services including global, regional and local team reorganisation, process optimisation, governance and systems assessment, skills and capabilities evaluation, and external benchmarking.

Companies that use Wickenstones

Customer profile

Segments2 records

Ideal customer profiles2 records

Wickenstones technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Wickenstones partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Wickenstones competitors and assessment

Company assessment

Direct peers

  • Evidera (PPD): Dedicated HEOR, market access, real-world evidence, and HTA consultancy serving pharma and biotech — overlapping capability set across all ten of Wickenstones' service areas.
  • Valid Insight (a Validant company): Pharma market access and pricing consultancy offering global pricing strategy, value communications, and stakeholder engagement — comparable capability footprint to Wickenstones.
  • Putnam Associates: Strategy consulting firm focused on pharmaceutical and biotech clients, with deep market access, pricing, and HEOR expertise — directly comparable to Wickenstones' service offering.
  • Maverex: Boutique pharma market access and HTA consultancy based in the UK, focused on payer engagement, submissions, and value communication — overlapping service mix with Wickenstones.
  • Cytel: Statistical, HEOR, and real-world evidence consultancy serving pharma and biotech — provides market access, HTA support, and economic modelling services comparable to Wickenstones' capabilities.
  • Mtech Access: UK-based market access, HTA, and HEOR consultancy with similar size and specialisation to Wickenstones, serving pharma clients across the UK and EU.

Broad incumbents

  • IQVIA (Commercial & HEOR): Large-scale life sciences services and analytics provider with an established consulting and HEOR practice; competes for the same enterprise pharma market access and HTA engagements as Wickenstones but at significantly greater scale.
  • Charles River Associates (Life Sciences): Global consulting firm with a life-sciences practice covering pricing, market access, and commercial strategy — competes for enterprise pharma strategy mandates with Wickenstones but at materially greater scale.
  • McKinsey (Pharma & Medical): Global management consultancy with a dedicated pharma practice covering market access, launch strategy, and organisational design — broader portfolio but competes for top-tier strategic pharma mandates.

Others

  • BIA (Bundesverband der Arzneimittel-Hersteller): German pharma industry association providing policy, market access, and HTA-related advisory support — adjacent to Wickenstones' HTA and stakeholder engagement capabilities in the European market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Wickenstones social profiles

Digital presence

Wickenstones financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wickenstones leadership team

Management profile

Number of profiles

Profiles17 records

Wickenstones funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wickenstones M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wickenstones

What does Wickenstones do?

Wickenstones is a pharmaceutical and life sciences consultancy providing integrated evidence, access, commercial, and medical advisory services. It delivers ten capability areas — Health Technology Assessment, Global Pricing, Evidence Review, Evidence Generation, Economic Modelling, Market Research, Value Communications, Route to Market Planning, Stakeholder Engagement, and Organisational Strategy and Design — through dedicated, multidisciplinary teams wrapped around each client engagement.

Is Wickenstones a public or private company?

Wickenstones is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Wickenstones founded?

Wickenstones was founded in 2013. It employs 11 to 50 people.

Where is Wickenstones based?

Wickenstones is headquartered in Abingdon, United Kingdom, in the Europe region.

How does Wickenstones make money?

One revenue line is on record: consulting Services.

Who are Wickenstones's main competitors?

Direct peers on record are Evidera (PPD), Valid Insight (a Validant company), Putnam Associates, Maverex, Cytel and Mtech Access. Broad incumbents are IQVIA (Commercial & HEOR), Charles River Associates (Life Sciences) and McKinsey (Pharma & Medical). BIA (Bundesverband der Arzneimittel-Hersteller) is listed as an others.

Does Wickenstones have an API?

No public API is recorded for Wickenstones.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales